Results 91 to 100 of about 28,689 (318)

Ruxolitinib and survival improvement in patients with myelofibrosis [PDF]

Leukemia, 2014
n ...
Passamonti, F., VANNUCCHI, ALESSANDRO MARIA, Cervantes, F., Harrison, C., Morra, E., Kantarjian, H., Verstovsek, S.   +6 more
openaire   +5 more sources

Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity

Biochemistry and Biophysics Reports, 2020
Ruxolitinib is a small-molecule protein kinase inhibitor, which is used as a therapeutic agent against several diseases. Due to its anti-inflammatory impact, ruxolitinib has also been considered recently for usage in the treatment of Covid-19.
Markus Fischer, Meike Luck, Maximilian Werle, Holger A. Scheidt, Peter Müller   +4 more
doaj   +1 more source

Pharmacoeconomics Of Ruxolitinib Therapy In Patients With Myelofibrosis [PDF]

Value in Health, 2015
Overall survival (OS) and other important clinical trial end-points seem increasingly more elusive in supporting rapid and efficient incorporation of innovative cancer drugs in clinical practice. This study proposes a clinical trial based pharmacoeconomic framework to assess the therapeutic and economic value of ruxolitinib in patients with ...
João Almeida, Valeska Andreozzi, João Paulo Fernandes Felix, Björn Vandewalle   +3 more
openaire   +4 more sources

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica, 2015
Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies.
Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek   +14 more
doaj   +1 more source

The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]

, 2020
Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M, Fleischman, Angela G, Huynh, Christy, Morse, Sarah J, Nguyen, Hellen, Nguyen, Jenny, Nguyen, Thanh Kim   +6 more
core  

COVID‐19 Infection Confirmed by Bronchoalveolar Lavage Fluid Metagenomics ‐Next‐Generation Sequencing Instead of Pharyngeal Swabs in Follicular Lymphoma: Three‐Case Report and Literature Review

Journal of Clinical Laboratory Analysis, EarlyView.
ABSTRACT Background Hematologic malignancy patients with B lymphocytopenia after anti‐CD20 monoclonal antibody or anti‐CD19 chimeric antigen receptor (CAR) T cell therapy often face prolonged SARS‐CoV‐2 positivity on pharyngeal swabs and persistent or recurrent COVID‐19 infection, resulting in high mortality.
Can Liu, Yupeng Song, Siyan Niu, Yili Jiang, Tingting Zhu, Xin Li, Rui Cui, Qi Deng   +7 more
wiley   +1 more source

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era

Haematologica
The recent progress with ruxolitinib treatment might improve quality-of-life as well as overall survival in patients with primary myelofibrosis (PMF).
Yosuke Okada, Hideki Nakasone, Shunto Kawamura, Kosuke Takano, Kazuki Yoshimura, Masaharu Tamaki, Akari Matsuoka, Takuto Ishikawa, Tomohiro Meno, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Machiko Kusuda, Aki Tanihara, Shun-ichi Kimura, Shinichi Kako, Yoshinobu Kanda   +18 more
doaj   +1 more source

STAT3 the oncogene - still eluding therapy? [PDF]

, 2015
The STAT family of transcription factors (signal transducers and activators of transcription) transduce signals from cytokine receptors to the nucleus, where STAT dimers bind to DNA and regulate transcription.
Akira, Alas, Amin, Badve, Barbieri, Bendell, Berclaz, Bhargava, Boehm, Bromberg, Bromberg, Buettner, Cao, Chakraborty, Chan, Chase, Choi, Chung, Claudinon, Dabir, Dauer, Debnath, Dechow, Demaria, Dercamp, Dhanik, Dias, Duong, Dvorak, Gao, Garcia, Garcia, Goodwin, Graham, Hao, Hedvat, Hemmann, Hevehan, Ho, Hu, Huang, Huang, Huang, Iwamaru, Kang, Kortylewski, Kunigal, Lee, Lee, Levine, Li, Lin, Liu, Maritano, Mesa, Migone, Miklossy, Miyoshi, Nagel-Wolfrum, Nefedova, Nguyen, Ogura, Park, Park, Pilati, Pranada, Regis, Ren, Schuringa, Schust, Schust, Sen, Sethi, Siddiquee, Song, Spitzner, Starr, Takeda, Tell, Timofeeva, Timofeeva, Turkson, Turkson, Viguier, Vinkemeier, Watson, Weber-Nordt, Wong, Xu, Xu, Xu, Yoo, Yoshikawa, Zhang, Zhang, Zhang   +95 more
core   +2 more sources

Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate

JEADV Clinical Practice, EarlyView.
Capsule Summary We present a case of a 31‐year‐old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis, who showed poor response to prior treatments. Following the initiation of a combination therapy with tofacitinib and methotrexate, significant improvements in joint pain and hair regrowth were observed. This case underscores
Jan Nicolai Wagner, Matthias Augustin, Caroline Gewiss, Carolin Grote, Nesrine Ben‐Anaya   +4 more
wiley   +1 more source